Literature DB >> 3009703

An inactivated hepatitis A viral vaccine of cell culture origin.

P J Provost, J V Hughes, W J Miller, P A Giesa, F S Banker, E A Emini.   

Abstract

Hepatitis A virus (HAV) strain CR326, adapted to grow in LLC-MK2 cells, was highly purified, inactivated with formalin, adsorbed to alum, and tested for capacity to induce antibody to HAV in both mice and marmosets. The minimum dose of HAV antigen necessary to produce antibody in 50% of mice was 10 ng. As little as three doses of 1 ng each produced antibody in 50% of marmosets. Further, all marmosets with any detectable antibody to HAV, as a result of vaccination, were protected against virulent infection on challenge with HAV. Thus a highly efficacious, inactivated hepatitis A vaccine can be produced from virus grown in cell culture. Although LLC-MK2 cells are unacceptable for use in human vaccine preparation, HAV can also be prepared in a similar manner in MRC-5 cells, which are acceptable for human vaccine manufacture.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009703     DOI: 10.1002/jmv.1890190105

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  12 in total

Review 1.  The development of vaccines: how the past led to the future.

Authors:  Stanley A Plotkin; Susan L Plotkin
Journal:  Nat Rev Microbiol       Date:  2011-10-03       Impact factor: 60.633

2.  Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus.

Authors:  J I Cohen; B Rosenblum; J R Ticehurst; R J Daemer; S M Feinstone; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

3.  History of vaccination.

Authors:  Stanley Plotkin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

4.  Hepatitis transmission among the Sioux Indians of South Dakota.

Authors:  F E Shaw; C N Shapiro; T K Welty; W Dill; J Reddington; S C Hadler
Journal:  Am J Public Health       Date:  1990-09       Impact factor: 9.308

Review 5.  Chemical Attenuation in the Development of a Whole-Organism Malaria Vaccine.

Authors:  Amber I Raja; Danielle I Stanisic; Michael F Good
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

6.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

7.  Evaluation of inactivated hepatitis A vaccine in Canadians 40 years of age or more.

Authors:  D W Scheifele; G J Bjornson
Journal:  CMAJ       Date:  1993-02-15       Impact factor: 8.262

8.  Successful Vaccines.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Curr Top Microbiol Immunol       Date:  2018-07-26       Impact factor: 4.291

Review 9.  The Discovery of Hepatitis Viruses: Agents and Disease.

Authors:  Mohammad S Khuroo; Ahmad A Sofi
Journal:  J Clin Exp Hepatol       Date:  2020-04-20

Review 10.  Cell Culture Systems and Drug Targets for Hepatitis A Virus Infection.

Authors:  Tatsuo Kanda; Reina Sasaki; Ryota Masuzaki; Naoki Matsumoto; Masahiro Ogawa; Mitsuhiko Moriyama
Journal:  Viruses       Date:  2020-05-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.